Evidence map›Paper›PMID 26196284›Full record

ArticlePloS one2015

Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy.

Zining Jin, Wenqian Wang, Nan Jiang, Lei Zhang, Yiming Li, Xiaoyin Xu, Shouliang Cai, Liang Wei, Xuhong Liu, Guanglei Chen and 5 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 24 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Zining JinDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Wenqian WangDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Nan JiangDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Lei ZhangDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Yiming LiDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Xiaoyin XuDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Shouliang CaiDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Liang WeiDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Xuhong LiuDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Guanglei ChenDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Yizhen ZhouDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Cheng LiuDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Zhan LiDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Feng JinDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Bo ChenDepartment of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
First Hospital of China Medical University · CNChina Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer is a high-risk breast cancer with poor survival rate. To date, there is a lack of targeted therapy for this type of cancer. One unique phenomenon is that inflammatory breast cancer is frequently triple negative. However, it is still ambiguous how inflammation influences triple-negative breast cancer growth and responding to chemotherapy. Herein, we investigated the levels of inflammation-associated enzyme, iNOS, in 20 triple-negative breast cancer patients' tumors, and examined its correlation with patients' responses to platinum-based neoadjuvant chemotherapy. Our studies showed that triple-negative breast cancer patients with attenuated iNOS levels in tumor cells after treatment showed better responses to platinum-based neoadjuvant chemotherapy than other triple-negative breast cancer patients. Our further in vitro studies confirmed that induction of proper levels of NO increased the resistance to cisplatin in triple-negative MDA-MB-231 cells. Our data suggest that aberrant high level of iNOS/NO are associated with less effectiveness of platinum-based neoadjuvant chemotherapy in triple-negative breast cancer. Therefore, we propose to monitor iNOS levels as a new predictor for triple-negative breast cancer patient's response to platinum-based neoadjuvant chemotherapy. Moreover, iNOS/NO is considered as a potential target for combination therapy with platinum drugs for triple-negative breast cancer.

Indexed as

Antineoplastic AgentsCell Line, TumorCisplatinDrug Resistance, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansNeoadjuvant TherapyNitric OxideNitric Oxide Synthase Type IITreatment OutcomeTriple Negative Breast NeoplasmsAntineoplastic AgentsCisplatinNitric OxideNitric Oxide Synthase Type IINOS2 protein, human

Identifiers

PMID26196284
PMCPMC4510059
OpenAlexW951658609

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.